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Abstract
Cardiovascular  diseases  (CVDs)  are  major  outcomes  of  metabolic  impairments  in
humans, which result from several genetic and environmental factors. In recent years,
a ‘microbiome hypothesis’ has been proposed as a result of several studies that have
attempted to understand underlying mechanisms of  CVDs.  Similar  to CVDs,  both
genetic and environmental factors, especially diets, have a major impact on shaping gut
microbiota and their functions. In the past decade, strong evidence has emerged to
confirm the role of gut microbiota in contributing to the onset of CVDs. However, a
comprehensive understanding of interactions among diet, host genotype, gut micro‐
biota and CVDs is still facing challenges due to the complicated nature of CVDs. In this
chapter, we review the present state of our knowledge about the contributory role of
gut  microbiota  in  CVDs  and  discuss  the  knowledge  gaps  that  warrant  further
investigations. Moreover, we review the potential intervention strategies that may target
the microbiota‐driven pathology in CVDs and discuss the strength and weakness of
animal models in studying the roles of gut microbiota in CVDs.
Keywords: gut microbiome, cardiovascular disease, host genotype, diet
1. Introduction
Cardiovascular disease (CVD) is a leading cause of death in industrialized societies, with
increasing incidence in developing countries [1]. A combination of genetic and environmental
factors contributes to risk for developing CVD [2]. A significant portion of CVDs can be
attributed to ischemic heart disease, often a result of underlying coronary arterial diseases
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such as atherosclerosis. Risk factors for atherosclerosis include dyslipidaemia, hypertension,
obesity, smoking, and diabetes [3, 4]. Extensive searching in recent years for causal genetic
variants found less than one‐fifth of CVD risk is accounted for by genetic determinants [5, 6].
Excluding tobacco exposure, dietary intake is our largest environmental risk, as we consume
kilogram quantities into our bodies daily. However, specific dietary composition and precise
quantification of dietary intake of a given individual are often difficult to assess.
Over the past decade, there has been a growing body of knowledge on the ecological diversity
of microbes living symbiotically within us, especially in our gastrointestinal tract. More than
100 trillion microbial cells reside in the human gut, which is far outnumbering the host cells
of the human body [7]. Microbial symbionts in our gastrointestinal system have coevolved
with us and critically contribute to a variety of physiologic and metabolic processes of our
body. Undeniably, human DNA is estimated to represent less than one‐tenth of the total DNA
within our bodies due to the remarkably large number of microorganisms in and on us, mainly
within our gastrointestinal tract [8]. The composition of the microbial community in our gut
can be largely affected not only by dietary exposures but also by genetic variants of the host,
as well as any changes that impaired host’s physiology and homeostasis. In recent years,
although there is increasing evidence supporting an association between gut microbiota and
diseases in human and animals [9, 10], the participatory roles of gut microbiota in our health,
immune function, and disease initiation and progression have just begun to be explored. There
has been an established understating of the role of microbial dysbiosis in the pathogenesis of
some diseases of altered intestinal health [11]. The alteration of gut microbiota may contribute
enormously to the digestion of food and absorption of metabolites, which further contribute
to the development of a range of CVDs from atherosclerosis to cardiorenal dysfunction [12].
The gastrointestinal ecosystem is arguably the largest endocrine as well as paracrine organ
in the body, producing a variety of biologically active compounds that may be transported
in the systemic circulation and distributed to other organ systems within the host, thereby
influencing diverse essential biochemical processes [12]. This chapter summarizes recent
developments in our knowledge of the contributory role of gut microbiota on the initial
onset and development of CVDs, and how diets and genetics of the host participate in their
development. Potential strategies that can modulate gut microbiota for prevention and
therapeutic interventions for CVDs will also be discussed.
2. Intestinal microbiota in cardiovascular disease—the good, the bad, and
the ugly
The understanding of the link between gut microbiota and CVD was limited until the late
1990s. The fact that axenic (germ‐free) ApoE knockout mice were not protected from the
development of atherosclerosis suggested that the gut microbiota is not important in the
pathogenesis of atherosclerosis [13]. A meta‐analysis of clinical trials revealed that the
modification of gut microbiota by antibiotics failed to demonstrate any benefit with regard to
mortality due to cardiovascular events in coronary artery disease patients [14]. Furthermore,
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in an extensive study involving 4012 patients with stable coronary artery disease, the admin-
istration of azithromycin showed no effect on the risk of cardiac events [15]. However, the
composition of the microbiota was shown to increase the severity of myocardial infarction in
a Dahl S rat model of ischaemia/reperfusion injury of the heart, in which the authors indicated
that vancomycin, a poorly absorbable antibiotic, reduced 27% of myocardial infarctions and
increased 35% postischaemic mechanical function recovery [16]. This effect was associated
with a change in the gut microbiota (both bacteria and fungi) and a reduction of plasma leptin,
which was later confirmed by administration of the leptin-suppressing probiotic Lactobacillus
plantarum 299v [16]. These earliest contradictory findings of antibiotic utilization (azithromycin
vs. vancomycin) explained the complexity of gut microbiota-based intervention in terms of
efficacy and properties of the applied protocol.
Figure 1. Gut microbiota and its impacts on atherosclerosis and major cardiovascular events through both nutrient/
meta-organismal pathways that contribute TMAO formation and translocation of bacterial toxins that cause myocar-
dial cell damage.
Invasion of indigenous and/or pathogenic oral and intestinal bacteria, as well as their metab-
olites and toxins into the vascular system, has been demonstrated in association with several
CVD events [17, 18], although a causal association between periodontal infection and athero-
sclerotic CVD or its sequel has not been demonstrated. Periodontitis, also known as perio-
dontal disease (PD), is an inflammatory disease of the oral cavity due to chronic bacterial
infection of soft and hard tissues of the gum, mainly by Gram-negative bacteria [19]. A high-
fat diet can induce not only metabolic alteration but also increased systolic and diastolic
pressure in diabetic mice after longer term colonization with periodontal pathogens, such as
Porphyromonas gingivalis, Prevotella intermedia, and Fusobacterium nucleatum [20]. The molecular
mechanisms underlying this pathogenic phenotype is linked to bacterial lipopolysaccharide
(LPS), which may increase oxidative stress and mitochondrial dysfunction that are responsible
for inflammation-induced CVD (Figure 1) [21]. Endotoxin levels were shown to be higher in
the hepatic veins compared with the left ventricle (LV) or pulmonary artery, suggesting
possible endotoxin translocation from the gut into the circulation [22].
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In recent years, more studies have highlighted the contributory role of gut microbiota in CVD.
Initial hypothesis‐generating studies using untargeted metabolomics analyses of plasma
samples identified three metabolites, including phosphatidylcholine (PC; lecithin) metabo‐
lism‐choline, betaine, and trimethylamine‐N‐oxide (TMAO) that are potentially associated
with cardiovascular risk [23]. Another study also found increased concentration of the
metabolite TMAO in patients with atherosclerosis and their correlation with this pathology
[24]. Gut microbiota has been demonstrated to be responsible for TMAO synthesis by con‐
verting choline, an essential nutrient, into TMA. Subsequent oxidation of TMA through flavin
monooxygenase 3 (FMO3) from the liver formed TMAO [25–27]. As an example, the bacteria
belonging to Erysipelotrichia under the phylum Firmicutes can metabolize choline to TMA [24].
TMA is subsequently absorbed and rapidly oxidized by hepatic cells to form TMAO [28], which
is responsible for macrophage foam cell formation by reducing reverse cholesterol transport
and consequently promoting cholesterol accumulation in the foam cells of atheroma (Fig‐
ure 1) [29]. However, the molecular mechanisms by which TMAO reduces reverse cholesterol
transport are not well understood. These bacteria probably promote not only atherosclerosis
through TMA‐TMAO production but also non‐alcoholic fatty live disease (NAFLD) by
reducing choline availability for the synthesis of very low‐density lipoprotein in the liver,
resulting in triglyceride accumulation in the hepatocytes [30]. Furthermore, the abundance of
such bacteria is also associated with an iron‐rich diet. Such a diet promotes gut epithelial cell
stress through iron accumulation in the enterocytes and consequently inflammation‐induced
dysbiosis of the gut microbiota in favour of Erysipelotrichia bacteria. Thus, an iron‐rich diet may
promote the development of NAFLD and atherosclerosis through alteration of the gut
microbiota [31]. The dysbiosis of gut microbiota has been found in several metabolic diseases,
including CVD. However, in different situations, dysbiosis can either be a cause or an effect of
the disease or a spiralling cycle. In the case of CVDs, the dysbiosis of gut microbiota needs
further investigation to determine whether it is cause or effect or both. Beside TMAO, intestinal
bacteria produce certain toxins, such as indoxyl sulphate, p‐cresyl sulphate, amines, and
ammonia, which can later be eliminated by the kidneys in healthy individuals. In chronic
kidney disease patients, however, these toxins may accumulate in the body of the patients.
In addition to the three bacterial metabolites described previously, l‐carnitine has also been
shown to accelerate atherosclerosis in mouse models, but only in the presence of intact gut
microbiota and TMA/TMAO generation. High carnitine levels significantly increased the risk
of myocardial infarction (MI), stroke, or death in experimental subjects with concurrently high
TMAO levels. Similar to PC/choline, l‐carnitine is a TMA‐containing compound that releases
TMA through the gut microbiota and consequently converted into TMAO by hepatic FMO
(Figure 1) [29]. Thus, intestinal microbiota may play an obligatory role in generating TMAO
from multiple dietary nutrients, and TMAO is the proatherogenic species probably promoting
the associations noted between plasma levels and both prevalent and incident CVD risks.
Recent studies reveal that the potential pathogenic contribution of gut microbiota‐dependent
generation of TMAO may extend beyond the development of progression of atherosclerosis
and its adverse complications (MI, stroke, or death). A recent observation also indicated
increased TMAO levels in heart failure patients [32]. In these patients, intestinal ischaemia can
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be demonstrated by a decrease in intestinal mucosal pH [33] or reduced passive carrier‐
mediated transport of d‐xylose [34]. Due to the consequences of intestinal ischaemia and
congestion, the morphology, permeability, and function of the intestinal mucosa may substan‐
tially altered in congestive heart failure (CHF), especially in advanced stages with cardiac
cachexia [35]. Our knowledge on the mechanistic associations between gut microbiota and
CHF is improving. Although evidence is still accruing, higher concentrations of adherent
bacteria have been identified in the intestinal mucosal biofilm of patients with CHF [35]. The
composition of intestinal microbiota may alter rapidly during intestinal ischaemia and
reperfusion or following an increase in portal vein pressure because of the activation on
bacterial virulence in microbiota by gut liminal hypoxia, hypercapnia, changes in local pH,
redox state, and norepinephrine [36]. Hypoperfusion and congestion in the intestine may
reduce cardiac output and further disrupt the barrier function of the intestine and promote
systemic inflammation through bacterial translocation, potentially leading to further CHF
exacerbations (Figure 2). However, major changes in the gut microbial composition have not
been observed in a rat model of CHF induced by coronary artery ligation [37]. In this regard,
the role of gut microbiota is possibly unique to human CHF.
Figure 2. Links between heart failure, gut microbiota, and renal failure. The haemodynamic variations caused by heart
failure affect microcirculation in intestinal villi and result in alternations of intestinal permeability and gut microbiota.
The increased intestinal permeability favours microbial and endotoxin translocation, TMAO, and cardiorenal compro‐
mises can mediate the pathology that leads to further exacerbation of heart failure and renal damage. Reduced clear‐
ance of these metabolites due to impaired renal function further promotes this pathology and constitutes a vicious
cycle.
The microbial analysis of atherosclerotic plaque has shown that the embedded microbiota is
dominated by bacteria of the phylum Proteobacteria (e.g. Escherichia coli) [38]. Proteobacteria are
also the most abundant microbiota in the blood of diabetic patients [39]. Hence, the establish‐
ment of microbiota might be the first step in the atherosclerotic plaque formation. Another
bacterium in the genus Collinsella was also found to be dominant in patients with symptomatic
atherosclerosis (presence of stenotic atherosclerotic plaques at the level of the carotid artery
and leading to cerebrovascular episodes). The same study also indicated that there were more
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bacteria belonging to Roseburia and Eubacterium in the gut microbiota of healthy controls
compared with patients [40]. Thus, the changes not only in microbiota composition but also
in microbiome functions may be linked with the events of atherosclerosis.
3. Role of diet and host genotype in shaping intestinal microbiota profile
associated with cardiovascular diseases
Dietary cholesterol has major effects on gastrointestinal microbiota, which is consequently
associated with the onset of CVD. In our recent study, we tested the effect of diet and host
genotype on intestinal microbiota using two Japanese quail strains that are atherosclerosis‐
susceptible (SUS) and atherosclerosis‐resistant (RES) [41]. In that study, dietary cholesterol
reduced the abundance of Ruminococcus and facilitated the abundance of opportunistic
pathogens belonging to Erysipelotrichaceae in the quail ceca and may have increased the risk of
assaults by these opportunistic pathogens. However, both the SUS and the RES strains housed
in the same cage and fed the same high cholesterol diet hosted distinctly different ceca
microbiomes.
When mice were fed a ‘Western diet’, which was high in fat and cholesterol, the overall
diversity of their gut microbiota dropped significantly due to a bloom of a class of Firmicutes
called Mollicutes, a member of which is Eubacterium dolichum [42]. E. dolichum has a number of
genomic features that could promote their own fitness in competition with other microbes in
the cecal nutrient metabolic milieu created by the host’s consumption of the Western diet. Their
abundance is associated with obesity in mice [42]. In our study, a similar situation may have
occurred in RES quail in their reaction to dietary cholesterol. The ceca of RES quail were
dominated by E. dolichum [41]. On the other hand, SUS quail fed the cholesterol diet had an
abundance of Lachnospiraceae in the ceca [41]. At the same time, the abundance of Ruminococ‐
caceae was not compromised [41]. Lachnospiraceae and Ruminococcaceae have been shown to be
associated with the maintenance of gut health [43, 44]. These two families are specialists for
degrading cellulose and hemicellulose components of plant materials, which are fermented
and converted into short chain fatty acids (SCFAs) readily absorbed and used by the host [45].
SCFAs play an important role in maintaining intestinal homeostasis [43, 44]. Our study
indicated that the divergent selection for susceptibility and resistance to diet‐induced athero‐
sclerosis may have adversely affected the cecal health of RES, but not SUS quail, through
modification of their cecal microbiomes [41]. Whether this change in the cecal environment
has effects on the metabolism and absorption of dietary cholesterol remains to be studied.
In the past decade, numerous studies have been published on the relationship between gut
microbiota and cardiovascular diseases in human and in animal models. In humans, about
50% of dietary cholesterol is absorbed in the duodenum; consequently, the rest can be me‐
tabolized by Eubacterium bacteria to coprostanol and minor amounts of coprostanone in the
large intestine [46]. Coprostanol, unlike cholesterol, is poorly absorbed by the human intes‐
tine, and hence, conversion of cholesterol to coprostanol might be a way to lower serum
cholesterol in humans and rodents [47, 48]. However, feeding Eubacterium coprostanoligenes
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to laying hens did not lower plasma cholesterol levels [49]. In our study using the quail
model, E. dolichum was found in higher abundance in the cecum of RES but not in SUS
quail [41]. Although a negative correlation of E. dolichum abundance with plasma HDL lev‐
el was significant in our study, the ability of E. dolichum to convert cholesterol to coprosta‐
nol has not been demonstrated. As the primary cholesterol absorption sites are in the small
intestine, a comprehensive examination of the microbiota in a complete set of intestinal
tract should be done to understand physiological variations at different anatomical loca‐
tions of the intestinal tract, which will further elaborate the potential targets by therapeutic
interventions. In the concurrent analysis on small intestinal microbiota of RES and SUS
quail fed the cholesterol diet, high abundance of Lactobacillus species were observed in both
ileum and duodenum [50] of RES but not in SUS quail. This finding is significant since
Lactobacillus species have been proposed as an effective probiotic to lower cholesterol in
humans [51].
A number of studies including our quail model highlighted the importance of host genotype
in responding to diet‐induced atherosclerosis. However, further research effort is need to
address the underlying biochemical pathways by which host genetics interplay with diets to
influence the CVD events through alteration of gut microbiota.
4. Animal models for studying gut microbiome in cardiovascular disease
Cardiovascular diseases (CVDs) involve complicated multifactorial pathologies, in which both
genetic and environmental factors are involved. In order to provide us with important insights
into the pathophysiology of CVD events, the development of animal models of CVD is essential
as tools to evaluate novel therapeutic strategies to predict and to prevent these complications.
Until now, there have been numbers of animal models used for CVD, including those imple‐
mented in both large (pig and dog) and small (mice and rat) animals, designed for enhancing
scope with more precision and to better represent human pathologies. With or without genetic
modifications, mouse, rat and rabbit models are more commonly used and less expensive
animal models for studying CVDs compared to porcine and canine models, which better
represent the human pathology, but are less popular due to the cost and difficulties in handling.
For atherosclerosis, mouse models have proven to be useful to study development and
progression of atherosclerotic lesions. In particular, knockout and transgenic mouse models
have been well developed to study the molecular and cellular mechanisms involved in
atherogenesis and to evaluate the effectiveness of new and existing drugs for the prevention
and/or treatment of atherosclerosis. The most widely used knockout mouse models include
low‐density lipoprotein receptor‐deficient mice (LDLR−/− mice) and apolipoprotein E‐deficient
mice (ApoE−/− mice). Mice carrying ApoE mutations such as ApoE3Leiden (E3L) and ApoE
(Arg 112→Cys→142) transgenic mice are very useful mouse models to study hyperlipidaemia
and atherosclerosis. The high‐cholesterol diet rabbit model has been widely used for experi‐
mental atherosclerosis [52]. Several porcine models have been employed for closer represen‐
tation to pathologies in humans [53–56]. However, the extensive application of porcine models
is still limited. In heart failure, dog models of myocardial infarction and serial microemboli‐
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zation of the coronary artery were developed [57]. Like the pig models, dog models are very
restricted due to their cost, ethical complications, and difficulties in handling.
Since the ‘microbiome hypothesis’ has been applied to CVDs and other metabolic diseases, the
most common and feasible animal model is the mouse model. As we know, murine models
have been extensively applied in biomedical research due to similarities in anatomy, physiol-
ogy, and genetics, which have allowed numerous inferences about human pathology to be
drawn from murine experimentation. In gut microbiota research, mouse models are being
increasingly used to study the role and functioning of the gut microbiota and its association
with diseases. However, application and direct translation of results obtained from traditional
CVD mouse models to study the role of the gut microbiome and its interaction with the host
have their limitations for the following reasons: [1] the variation of the gut microbiota of
laboratory mice relates to genetic, physiologic, and environmental factors, and those factors
also trigger the pathologies of CVD; [2] cross-talk between the gut microbiota and the host is
host-specific so observations in mouse models might not be applicable to humans; [3] the
inherent genetic variations in the human population cannot be captured by the inbred mouse
strains that have genetic homogeneity; and finally [4] differences in multiple factors between
mice and humans, such as genetic background, birth mode (caesarean or vaginal), mode of
feeding (breast or bottle), diet, age, medical history, and social activities, which all contribute
in shaping the gut microbiota of humans.
Existing animal models for CVDs have not yet been fully evaluated in studying the role of the
gut microbiome in developing pathologies of CVD events. This should be considered in future
investigations, and the most appropriate animal model to study the links between gut
microbiota and CVD should be proposed and recommended. Rabbits [58], guinea pig [59],
pigeon [60], and quail [61] have been used as models for studying atherosclerosis but not in
association with gut microbiota. Recently, we proposed a new quail model that would be useful
for studying the interaction of host genotype and diet in affecting the gut flora in association
with the development of atherosclerosis [41]. We proposed that our Japanese quail model may
have advantages over others because quail are naturally deficient in apolipoprotein E. When
we fed a high cholesterol diet, males of the SUS quail developed lesions exhibiting structural
features (e.g. focal haemorrhage, calcification, and fibrosis) that closely similar those in the
human atherosclerosis [62, 63]. In addition, quail model is easier to be handled, lower costs for
larger sample size, and require less laboratory space compared to other porcine or canine
models. As a further incentive, our recent microbiome study has provided the baseline
understanding for the association between the gut microbiome and the development of
atherosclerosis in quail model.
5. The potential of modulation of gut microbiota as novel preventive and
therapeutic strategies for cardiovascular disease
During these past few years, several research efforts aimed to modulate both structure and
function aspects of the gut microbiome were reported [64, 65]. Faecal transplantation is one of
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the successful stories for restoring impaired gut microbiome into normal gut microbiome,
which has shown certain success in applications of certain human diseases especially in
Clostridium difficile infection [66]. However, several underlying questions still have not been
fully resolved and more baseline information is needed. Likewise, therapeutic tools available
to modulate the microbiota‐driven pathogenesis of CVD remain to be validated. Besides the
well‐known faecal transplantation, the composition of gut microbiota can be modulated by
diet, antibiotics, and prebiotic/probiotics. If we are to modulate the microbiome functions or
biochemical pathways involved in microbiota‐driven pathology, the crosstalk (detail mecha‐
nisms) between host and microbiota becomes a major concern, and pharmacological inter‐
ventions are needed to target both host and microbiota metabolisms.
5.1. Dietary intervention
As choline, PC, and carnitine are primary sources of gut microbiota‐associated TMAO
production, dietary modulation is a logical intervention strategy [12]. It has been shown that
vegetarians and vegans have markedly reduced production of TMA and TMAO from dietary
l‐carnitine and have lower plasma TMAO levels than omnivores [29]. Similarly, studies have
shown that different gut microbial communities were found in vegetarians and vegans
compared with omnivores [29, 67]. In animal model studies, long‐term exposure to dietary l‐
carnitine increased TMA synthetic capacity by 10‐fold with a concurrent shift in gut microbial
composition [29]. Thus, chronic dietary exposure (e.g., omnivore vs. vegan/vegetarian among
humans or normal chow vs. chow plus l‐carnitine in mouse studies) shifts gut microbiota,
with a selective advantage for certain bacterial species that prefer l‐carnitine as a carbon fuel
source to increase in proportion within the community and amplify the potential to produce
TMA [12].
The elimination of l‐carnitine from the diet is a potentially achievable goal that may reduce
some TMAO production. But, choline is an essential nutrient and its complete elimination from
the diet is unwise. Furthermore, bile has a very high total choline (PC) content, and the rapid
turnover and sloughing of intestinal epithelial cells results in significant exposure of distal gut
segments (and hence microbes) to choline, independent of dietary intake. Absorbent removal
of TMA from the intestines by specific oral binding agents is a challenging but potentially
feasible therapeutic approach for reducing TMA and TMAO levels. The details of application
of binding reagents will be discussed in the following specific section.
5.2. Antibiotic intervention
The association between certain groups of bacteria and CVD such as atherosclerosis has
previously been postulated. However, a number of randomized controlled studies have failed
to demonstrate a benefit of antibiotic therapy for secondary prevention of cardiovascular
events [15, 68]. On the other hand, antibiotics can influence the pathophysiological outcomes
driven by changing the abundance or composition of the gut microbiota. A well‐known
antibiotic, vancomycin, presented a reduction of myocardial infarct size in a rat model of
ischaemia‐reperfusion [16]. Interestingly, there was no effect on severity of myocardial
infarction by direct infusion of vancomycin into the coronary circulation. Furthermore, the oral
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administration of the antibiotic polymyxin B reduced monocyte production of certain
proinflammatory cytokines in patients with HF and improved flow‐medicated dilation [69].
Although the previous findings reflect the effect of antibiotics in the modulation of gut
microbiota on the pathophysiology of various CVD events including HF, the potential adverse
effects of antibiotics, such as microbial substitution and generation of antibiotic‐resistant
microbes, commonly occur in clinical practices. Hence, the extensive application of this
strategy is arguable and challenging. Careful considerations are needed to minimize the
adverse effects of antibiotic agents. Additional investigations are needed to determine the
benefits of proper application of antibiotics in specific circumstances in clinical practices.
5.3. Prebiotic/probiotic intervention
Prebiotics are non‐digestible food ingredients, mainly fibres that beneficially affect the host’s
health by selectively stimulating the growth and/or activity of some genera of gut microor‐
ganisms especially in the hindgut. Probiotics are live microorganisms that confer a health
benefit to the host when administered in adequate amounts through improving the intestinal
microbial balance [70]. However, the effectiveness of both prebiotics and probiotics varies on
their sources, methods of preparation and administration, and the dosage. They have been
extensively applied in most gastrointestinal disorders, and recently their applications in
metabolic and cardiovascular diseases have been studied due to their potential role to
modulate gut microbiota that consequently may diminish the pathophysiology of those
diseases. In a study, done in a ‘humanized’ mouse model (germ‐free mice colonized with
human gut flora), the probiotic administration alters the production of several metabolites
including TMAO through modulation of symbiotic gut microbial‐host interactions [71].
Evidence has been provided that demonstrates that intervention with a probiotic product can
favourably affect cardiac morphology and function in animal models [16]. A leptin suppressing
probiotic bacteria, Lactobacillus plantarum, led to the attenuation of ischaemia‐reperfusion
injury in rats [16]. Additionally, in a rat myocardial infarction model, probiotic administration
(Lactobacillus rhamnosus GR‐1) reduced left ventricle (LV) hypertrophy and improved LV
ejection fraction (LVEF), without colonization in the gut [37]. In HF patients, a yeast probiotic,
Saccharomyces boulardii was shown to be beneficial by improving cardiac systolic function
(LVEF) and decreasing serum creatinine and C‐reactive protein (CRP) during short‐term
follow‐up [72]. Although probiotics have generated much attention for improving CVD [37,
73], the attention on prebiotics has been limited due to its unclear definition and unfeasible
applications [69]. Non‐digestible beta‐glucans have become one of the popular prebiotics for
improving several metabolic diseases and CVD. With limited research, they have shown
beneficial effects of non‐digestible beta‐glucans on CVD and metabolic diseases and their
modulatory effect on gut microbiota (reviewed in [74]). However, long‐term benefits of
prebiotic and probiotic intervention strategies remain to be determined. As we described
earlier in this chapter, host genotype significantly influences both the composition and
probably the function of the gut microbiome, which may further interact with administered
probiotics or prebiotics. Thus, the effectiveness of probiotic/prebiotic treatments may vary
depending on the host genotype.
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5.4. Binding agents of key mediators
As the metabolites (e.g. TMAO) and their precursors (e.g. TMA) play important roles in the
pathogenesis of CVD, a promising intervention would be to remove such metabolites and their
precursors from the gut by oral administration of specific non‐absorbent binding agents. Oral
charcoal absorbent (AST‐120) has been clinically applied to remove uremic toxins, such as
indoxyl sulphate, in patients with advanced renal failure [75]. AST‐120 has been shown to
prevent progression of LV hypertrophy and cardiac fibrosis in rats with chronic kidney
disease (CKD) [76] and in a combination model with CKD plus HF [77] without affecting blood
pressure. However, the efficacy of binding agents has not yet been demonstrated in human,
and more research should explore the potential use of such strategies.
6. Conclusion
Coevolution over millions of years between human and microorganism has led to a mutualistic
relationship, in which diverse ecosystems of gastrointestinal microbiota and its metabolic
functions contribute to the maintenance of our metabolic homeostasis. The interaction between
heart and gut, or the heart‐intestine axis, has emerged as a novel concept to provide new
insights into the complex mechanisms of CVD. Gut microbiota function as a filter for our largest
environmental exposure, our dietary intake, and the microbial community within each of us
obviously influences how we experience a diet. We need to appreciate that our gut microbial
ecosystem makes up a large and plastic endocrine organ that influences numerous metabolic
and physiological processes. Although recent sequencing efforts of gut microbiota provide
multiple evidences of its associations with CVD events, simply cataloguing the microbes
within is not sufficient and further studies should focus on discovery of the functional aspects
of microbiota and its metabolites that contribute to the pathophysiology of CVD and other
metabolic diseases that trigger CVD events. Not all currently available animal models are
suitable for discovering the role of gut microbiota on CVD and associated diseases, thus, new
in vivo models need to be developed and/or existing reliable models should be recommended
based on their reliability and better representation of the human condition. There is increasing
attention towards modulating the gut microbiota as a new target for therapeutic intervention
and targeting for treatment and prevention of complex cardiometabolic diseases. However, at
present time, the role of gut microbiota‐targeted interventions remains ambiguous due to the
absence of solid and well‐documented clinical evidence. Further advances in this area have
enormous potential in the development of novel therapeutic tools for microbiome modulation
of CVD.
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